Grifols Aims For Largely Untapped Market With Successful Fibrinogen Deficiency Study

The Phase III trial of BT524 produced positive topline results in patients with acquired fibrinogen deficiency, potentially making it the first fibrinogen concentrate to win US FDA approval for that indication.